These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32425128)

  • 1. Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery.
    Chen SD; Li HQ; Cui M; Dong Q; Yu JT
    Expert Opin Drug Discov; 2020 Sep; 15(9):1081-1094. PubMed ID: 32425128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
    Corti S; Faravelli I; Cardano M; Conti L
    Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.
    Cao L; Tan L; Jiang T; Zhu XC; Yu JT
    Mol Neurobiol; 2015 Aug; 52(1):244-55. PubMed ID: 25146848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.
    Okano H; Morimoto S
    Cell Stem Cell; 2022 Feb; 29(2):189-208. PubMed ID: 35120619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling.
    Beghini DG; Kasai-Brunswick TH; Henriques-Pons A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.
    Marotta N; Kim S; Krainc D
    Expert Opin Drug Discov; 2020 Apr; 15(4):427-441. PubMed ID: 31899983
    [No Abstract]   [Full Text] [Related]  

  • 10. Induced Pluripotency: A Powerful Tool for In Vitro Modeling.
    Zahumenska R; Nosal V; Smolar M; Okajcekova T; Skovierova H; Strnadel J; Halasova E
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.
    Engle SJ; Blaha L; Kleiman RJ
    Neuron; 2018 Nov; 100(4):783-797. PubMed ID: 30465765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in induced pluripotent stem cell research for age-related neurodegenerative diseases].
    Ito D; Yagi T; Suzuki N
    Brain Nerve; 2013 Mar; 65(3):283-8. PubMed ID: 23475520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing Drug Discovery for Neurological Disorders Using iPSC-Derived Neural Organoids.
    Costamagna G; Comi GP; Corti S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodegenerative disease-specific induced pluripotent stem cell research.
    Inoue H
    Exp Cell Res; 2010 Oct; 316(16):2560-4. PubMed ID: 20420829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research on neurodegenerative diseases using induced pluripotent stem cells.
    Imamura K; Inoue H
    Psychogeriatrics; 2012 Jun; 12(2):115-9. PubMed ID: 22712645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced pluripotent stem cells and neurological disease models.
    Cai S; Chan YS; Shum DK
    Sheng Li Xue Bao; 2014 Feb; 66(1):55-66. PubMed ID: 24553870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy.
    Dai S; Qiu L; Veeraraghavan VP; Sheu CL; Mony U
    Curr Stem Cell Res Ther; 2024; 19(6):809-819. PubMed ID: 37291782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegenerative diseases in a dish: the promise of iPSC technology in disease modeling and therapeutic discovery.
    Xie YZ; Zhang RX
    Neurol Sci; 2015 Jan; 36(1):21-7. PubMed ID: 25354658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
    Struzyna LA; Watt ML
    Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of induced pluripotent stem cells in drug development.
    Inoue H; Yamanaka S
    Clin Pharmacol Ther; 2011 May; 89(5):655-61. PubMed ID: 21430656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.